SD Biosensor Inc (137310) - Total Liabilities
Based on the latest financial reports, SD Biosensor Inc (137310) has total liabilities worth ₩495.94 Billion KRW (≈ $336.09 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 137310 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
SD Biosensor Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how SD Biosensor Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SD Biosensor Inc asset portfolio.
SD Biosensor Inc Competitors by Total Liabilities
The table below lists competitors of SD Biosensor Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nagarro SE
XETRA:NA9
|
Germany | €587.94 Million |
|
Dutch Lady Milk Industries Bhd
KLSE:3026
|
Malaysia | RM431.97 Million |
|
Transcoal Pacific Tbk PT
JK:TCPI
|
Indonesia | Rp1.88 Trillion |
|
Dymatic Chemicals Inc
SHE:002054
|
China | CN¥3.43 Billion |
|
PTC India Limited
NSE:PTC
|
India | Rs55.72 Billion |
|
Greenlight Capital Re Ltd
NASDAQ:GLRE
|
USA | $1.54 Billion |
|
Nueva Expresión Textil S.A.
MC:NXT
|
Spain | €51.93 Million |
|
Concord International Securities Co Ltd
TWO:5864
|
Taiwan | NT$4.29 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down SD Biosensor Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of SD Biosensor Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SD Biosensor Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SD Biosensor Inc (2019–2025)
The table below shows the annual total liabilities of SD Biosensor Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩905.85 Billion ≈ $613.88 Million |
-5.26% |
| 2024-12-31 | ₩956.18 Billion ≈ $647.99 Million |
-0.12% |
| 2023-12-31 | ₩957.28 Billion ≈ $648.74 Million |
+203.76% |
| 2022-12-31 | ₩315.14 Billion ≈ $213.57 Million |
-60.69% |
| 2021-12-31 | ₩801.72 Billion ≈ $543.32 Million |
+13.87% |
| 2020-12-31 | ₩704.10 Billion ≈ $477.16 Million |
+2113.84% |
| 2019-12-31 | ₩31.80 Billion ≈ $21.55 Million |
-- |
About SD Biosensor Inc
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volum… Read more